Pharmaceutical

Precision and Imugene conclude transaction for cancer drug azer-cel

Precision BioSciences and Imugene have concluded a strategic transaction for worldwide rights to the former’s allogeneic CAR T candidate

Aug 16, 2023 - 20:00
Precision and Imugene conclude transaction for cancer drug azer-cel
Precision BioSciences and Imugene have concluded a strategic transaction for worldwide rights to the former’s allogeneic CAR T candidate
Read the original article

Tags:

Previous Article

AGC and Asahi partner for clinical drug production in Seattle

Next Article

Leprosy potentially endemic in Central Florida

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

The biotech updates you need to read today

The biotech updates you need to read today

Dec 19, 2023

GITEX GLOBAL 2024: Huawei launches a series of industrial digital and intelligent transformation solutions, and flagship products

GITEX GLOBAL 2024: Huawei launches a series of industri...

Oct 16, 2024

Selinexor by Karyopharm Therapeutics for Wilms’ Tumor (...

Oct 27, 2023